Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Nantahala Capital Management LLC

Nantahala Capital Management LLC grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 37.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,665,529 shares of the company's stock after acquiring an additional 995,586 shares during the quarter. Amneal Pharmaceuticals comprises about 1.2% of Nantahala Capital Management LLC's portfolio, making the stock its 10th biggest position. Nantahala Capital Management LLC owned approximately 1.18% of Amneal Pharmaceuticals worth $29,031,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in AMRX. Mirae Asset Global Investments Co. Ltd. bought a new position in Amneal Pharmaceuticals in the fourth quarter worth about $81,000. Straightline Group LLC purchased a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $92,000. Cibc World Markets Corp bought a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $118,000. Janney Montgomery Scott LLC purchased a new stake in Amneal Pharmaceuticals during the fourth quarter valued at approximately $121,000. Finally, Fox Run Management L.L.C. boosted its stake in Amneal Pharmaceuticals by 69.0% in the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock valued at $162,000 after acquiring an additional 8,342 shares in the last quarter. 31.82% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now owns 1,808,886 shares of the company's stock, valued at approximately $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,160,000 shares of company stock valued at $43,113,200. 26.56% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of recent analyst reports. Barclays upped their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price target for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $10.80.

Amneal Pharmaceuticals Stock Up 3.0 %

Shares of AMRX traded up $0.23 during trading hours on Friday, reaching $7.97. 4,829,305 shares of the company traded hands, compared to its average volume of 1,424,376. The stock has a market capitalization of $2.47 billion, a P/E ratio of -11.72 and a beta of 1.17. The business has a fifty day moving average price of $8.02 and a 200-day moving average price of $8.17. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.81 and a 12-month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.